LifeSciences BC > News > Member Announcements

DelMar Presents Clinical Update on VAL-083 From Ongoing First- and Second-Line Trials in Patients with MGMT-unmethylated GBM at The Society for NeuroOncology Annual Meeting

November 20, 2018
DelMar Pharmaceuticals, Inc.

VANCOUVER, British Columbia and MENLO PARK, Calif., Nov. 20, 2018 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, presented scientific updates, including data from two ongoing clinical trials, at the 23rd Annual Meeting and Education Day of the Society for Neuro-Oncology (SNO) … Continue reading DelMar Presents Clinical Update on VAL-083 From Ongoing First- and Second-Line Trials in Patients with MGMT-unmethylated GBM at The Society for NeuroOncology Annual Meeting

ASPECT BIOSYSTEMS RECEIVES $2.7M INVESTMENT FROM THE GOVERNMENT OF CANADA

November 15, 2018

Government of Canada invests nearly $20M in top British Columbia companies in 2018 VANCOUVER, British Columbia – November 15, 2018 – Aspect Biosystems, a leader in the field of 3D bioprinting and tissue engineering, has received $2.7 million from the Government of Canada’s Western Innovation (WINN) Initiative. WINN has funded 17 projects in British Columbia … Continue reading ASPECT BIOSYSTEMS RECEIVES $2.7M INVESTMENT FROM THE GOVERNMENT OF CANADA

Zucara Therapeutics – Helping people with diabetes sleep safely and soundly

November 15, 2018
Zucara Therapeutics Inc.

Typically occurring overnight, hypoglycemia puts over 8 million people with diabetes at fatal risk during their sleep Current therapies offer hypoglycemic treatment only once an episode occurs Zucara is working on the first treatment to prevent hypoglycemia which can kill patients in their sleep November 14, 2018 – Vancouver, Canada: On World Diabetes Day, Zucara … Continue reading Zucara Therapeutics – Helping people with diabetes sleep safely and soundly

Precision NanoSystems and Entos Pharmaceuticals sign license agreement for the use of the NanoAssemblr® platform for scale-up and GMP manufacturing of nanomedicines

November 14, 2018
Precision NanoSystems Inc.

VANCOUVER , BC- November 13, 2018 Precision NanoSystems, Inc. (PNI) and Entos Pharmaceuticals (Entos) today announced they have entered into a license and supply agreement whereby PNI will provide its scale-up system, technology transfer and support the GMP manufacturing of Entos’ lead candidate. Entos will use the NanoAssemblr Blaze™ instrument for preclinical toxicology studies and transition … Continue reading Precision NanoSystems and Entos Pharmaceuticals sign license agreement for the use of the NanoAssemblr® platform for scale-up and GMP manufacturing of nanomedicines

Zymeworks Announces Updated Clinical Data for Novel Bispecific Antibody, ZW25, Presented at the EORTC-NCI-AACR Symposium

November 14, 2018
Zymeworks Inc.

ZW25 Active and Well Tolerated Across Multiple HER2-expressing Tumor Types Durable Anti-Tumor Activity with Confirmed Partial Responses and Median Progression-Free Survival > Six Months 82 Percent of Heavily Pretreated Patients Experienced Disease Control DUBLIN–(BUSINESS WIRE)– Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, announced today the plenary presentation of updated ZW25 clinical … Continue reading Zymeworks Announces Updated Clinical Data for Novel Bispecific Antibody, ZW25, Presented at the EORTC-NCI-AACR Symposium

DelMar Pharmaceuticals Announces First Quarter Fiscal Year 2019 Financial Results

November 14, 2018
DelMar Pharmaceuticals, Inc.

Company will host a business update conference call on November 20, 2018 at 4:30 PM Eastern Time VANCOUVER, British Columbia and MENLO PARK, Calif., Nov. 14, 2018 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of new cancer therapies, announced its financial results for the first quarter … Continue reading DelMar Pharmaceuticals Announces First Quarter Fiscal Year 2019 Financial Results

WAT Med Helps to Fight Cancer

November 13, 2018
WAT Medical Inc.

11/11/2018 – Vancouver, BC – MD Anderson Cancer Center is a globally recognized cancer research organization. With emphasis on cancer patient care, research, education, and prevention, the center is devoted to the goal of eliminating cancer worldwide. To support this cause, WAT Med will implement a donation system where starting from November 1st, 2018, $1 … Continue reading WAT Med Helps to Fight Cancer

Arbutus Reports 2018 Third Quarter Financial Results and Provides Corporate Update

November 7, 2018
Arbutus Biopharma Corporation

AB-506, a second-generation capsid inhibitor, advanced to HBV patient portion of Phase 1a/1b clinical trial – ONPATTRO™ (patisiran) approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), triggering a royalty stream to Arbutus Third Quarter Conference Call and Webcast Scheduled Today at 4:30 PM ET WARMINSTER, Pa., Nov. 07, 2018 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading … Continue reading Arbutus Reports 2018 Third Quarter Financial Results and Provides Corporate Update

Xenon Pharmaceuticals to Present at the Stifel 2018 Healthcare Conference

November 7, 2018
Xenon Pharmaceuticals Inc.

BURNABY, British Columbia, Nov. 07, 2018 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon’s Chief Executive Officer, will present a corporate update at the Stifel 2018 Healthcare Conference in New York, NY on Tuesday, November 13, 2018 at 9:30 am ET. A live audio webcast … Continue reading Xenon Pharmaceuticals to Present at the Stifel 2018 Healthcare Conference

Aquinox Pharmaceuticals Announces Third Quarter 2018 Financial Results

November 7, 2018
Aquinox Pharmaceuticals, Inc

VANCOUVER, British Columbia, Nov. 07, 2018 (GLOBE NEWSWIRE) — Aquinox Pharmaceuticals, Inc. (“Aquinox“) (NASDAQ:AQXP), a pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood cancers, today provided a corporate update and reported financial results for the third quarter ending September 30, 2018. “We ended the third quarter with $86.7 million in cash and cash equivalents … Continue reading Aquinox Pharmaceuticals Announces Third Quarter 2018 Financial Results